Arch Biopartners Inc.
ACHFF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $158 | $0 | $118 | -$361 |
| % Growth | – | -100% | 132.6% | – |
| Cost of Goods Sold | $0 | $130 | $102 | $390 |
| Gross Profit | $43 | -$130 | $16 | -$750 |
| % Margin | 27.4% | – | 13.3% | 207.8% |
| R&D Expenses | $90 | $106 | $78 | $417 |
| G&A Expenses | $226 | $289 | $251 | $247 |
| SG&A Expenses | $227 | $365 | $256 | $250 |
| Sales & Mktg Exp. | $1 | $76 | $4 | $4 |
| Other Operating Expenses | -$42 | $118 | $39 | -$269 |
| Operating Expenses | $275 | $588 | $373 | $398 |
| Operating Income | -$275 | -$588 | -$357 | -$1,148 |
| % Margin | -174.2% | – | -302.9% | 318% |
| Other Income/Exp. Net | $33 | -$36 | -$59 | $44 |
| Pre-Tax Income | -$242 | -$624 | -$416 | -$1,104 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$242 | -$624 | -$416 | -$1,104 |
| % Margin | -153.3% | – | -352.9% | 305.8% |
| EPS | -0.004 | -0.01 | -0.006 | -0.018 |
| % Growth | 61.5% | -50% | 64.8% | – |
| EPS Diluted | -0.004 | -0.01 | -0.006 | -0.018 |
| Weighted Avg Shares Out | 66,106 | 64,941 | 64,941 | 60,770 |
| Weighted Avg Shares Out Dil | 66,106 | 64,941 | 64,941 | 60,770 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $59 | $67 | $70 | $117 |
| Depreciation & Amortization | $0 | $507 | $253 | $1,013 |
| EBITDA | -$183 | -$51 | -$93 | $0 |
| % Margin | -116.1% | – | -78.6% | -0% |